Q3 2024 Acurx Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Acurx Pharmaceuticals Inc (ACXP) presented positive results from their phase two clinical trial for C. diff infection, indicating strong clinical efficacy.
- The company received a new patent for their treatment, Ibezapolstat, which could provide a competitive advantage until 2042.
- Acurx Pharmaceuticals Inc (ACXP) achieved CMC readiness for phase three trials, indicating regulatory progress.
- The company is exploring international regulatory pathways, starting with the European Medicines Agency, to expand market reach.
- Acurx Pharmaceuticals Inc (ACXP) is actively pursuing non-dilutive funding options, including government partnerships and territorial licenses, to support phase three trials.
- The company reported a decrease in cash reserves, from $7.5 million at the end of 2023 to $5.8 million by September 2024.
- Acurx Pharmaceuticals Inc (ACXP) experienced a net loss of $2.8 million for the third quarter of 2024, indicating ongoing financial challenges.
- Research and development expenses increased over the nine months ending September 2024, reflecting higher manufacturing costs.
- General and administrative expenses rose by $1.3 million over the same period, driven by increased professional and legal fees.
- The company has not yet secured a major pharmaceutical partnership, which could delay funding and progress for phase three trials.
Greetings and welcome to the Accurate Pharmaceuticals Inc third quarter, 2024 results and business update conference call at this time. All participants are in a listen-only mode, a brief question and answer session will follow the formal presentation. Should anyone require operator assistance during the conference? Please press star zero on your telephone keypad as a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Robert Shawah, Chief Financial Officer. Thank you. You may begin.
Thank you. Good morning and welcome to our call this morning, we issued a press release providing financial results and company highlights for the third quarter of 2024 which is available on our website at Aerex Pharma dotcom.
Joining me today is Dave Lucci, President and CEO of ACX.
We'll give a corporate update and outlook after that. I'll provide some highlights of the financials for the quarter ended September 30th 2024 and then turn the call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
